Closing Gaps in Personalized NSCLC Care Through Implementation of High-Quality Precision Programs
October 16, 2026 – October 16, 2027
This activity is jointly provided by Global Education Group (Global) and GO2 for Lung Cancer.
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
The primary audience for this project is multidisciplinary healthcare professionals (HCPs) involved in the diagnosis, treatment, and longitudinal care of patients with advanced mNSCLC, including those with HER2 (ERBB2)-mutations. This includes medical oncologists, nurse practitioners, physician assistants, oncology pharmacists, molecular pathologists, oncology nurses and navigators, and other team members integral to diagnosis, biomarker testing, treatment selection, and toxicity management, especially those practicing in community, under-resourced, and rural settings, where disparities in access to biomarker testing and targeted therapies remain most pronounced.
In this activity, faculty examine practical strategies for building patient-centered systems of care that ensure timely, equitable, and comprehensive biomarker testing for patients with non-small cell lung cancer (NSCLC), with a focus on HER2 (ERBB2)-mutant disease.
This activity explores best practices for integrating comprehensive next-generation sequencing (NGS) into routine clinical workflows, reducing delays from biopsy to treatment, and implementing repeat biomarker testing at disease progression, recurrence, or the diagnosis of a new primary malignancy.
The faculty also discuss innovative approaches to extending expert care through multidisciplinary collaboration, Project ECHO, telehealth, and remote monitoring technologies to support patients receiving targeted and nontargeted therapies. Finally, participants will learn how to evaluate biomarker testing performance through meaningful data collection and quality dashboards that track key metrics, including time to biopsy, time to NGS results, and time to treatment, to drive continuous quality improvement and optimize patient outcomes.
By the end of this activity, learners will be equipped with practical, evidence-based strategies to strengthen precision oncology care pathways and improve access to timely, biomarker-guided treatment for patients with HER2 (ERBB2)-mutant NSCLC.
After completing this activity, the participant should be better able to:
Sarah Goldberg, MD, MPH
Associate Professor of Medicine, Medical Oncology Section
Yale School of Medicine
Paul Stockhammer, MD, PhD
Hematology / Medical Oncology Fellow
Smilow Cancer Center - Yale New Haven Hospital
30-minute online activity
In support of improving patient care, this activity has been planned and implemented by Global Education Group and GO2 for Lung Cancer. Global Education Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Global Education Group designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Education Group designates this continuing education activity for 0.5 contact hour(s) including 0.0 pharmacotherapeutic contact hour(s).
Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by Joint Accreditation and all other accrediting bodies, as applicable, stating those activities where CE credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited CE program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are appropriately identified as relevant by Global. All relevant financial relationships have been mitigated in advance of delivery of the activity to learners.
For information about the Joint Accreditation (ACCME, ANCC) of this activity, please contact Global at 303-395-1782 or [email protected].
